Metformin protects against small intestine damage induced by diabetes and dunning's prostate cancer: A biochemical and histological study.

Autor: Dagsuyu E; Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpaşa, Istanbul, Türkiye. eda.dagsuyu@iuc.edu.tr., Koroglu P; Department of Histology and Embryology, Faculty of Medicine, Halic University, Istanbul, Türkiye., Bulan OK; Department of Biology, Faculty of Science, Istanbul University, Istanbul, Türkiye., Gul IB; Department of Biology, Faculty of Science, Istanbul University, Istanbul, Türkiye., Yanardag R; Department of Chemistry, Faculty of Engineering, Istanbul University-Cerrahpaşa, Istanbul, Türkiye.
Jazyk: angličtina
Zdroj: Journal of molecular histology [J Mol Histol] 2024 Dec; Vol. 55 (6), pp. 1093-1105. Date of Electronic Publication: 2024 Aug 31.
DOI: 10.1007/s10735-024-10252-y
Abstrakt: The oral biguanide metformin is used to treat type 2 diabetic mellitus (T2DM). Anti-cancer effects have been proven by metformin in different hormone-sensitive tumors, including breast, pancreatic, colon, and prostate cancer. Therefore, we investigated whether metformin could defend against small intestine damage in Dunning's prostate cancer. The study divided the six groups of male Copenhagen rats into the following categories: control, diabetic (D), cancer (C), diabetic + cancer (DC), cancer + metformin (CM), and diabetic + cancer + metformin (DCM). After sacrifice, the small intestines were removed to assess biochemical markers and histopathological evaluation. Biochemical evaluations showed that glutathione (reduced) levels and other enzyme activities related antioxidant systems, paraoxonase, sodium potassium ATPase, acetylcholinesterase activities were decreased. In contrast, lipid peroxidation, total oxidant status, reactive oxygen species, interleukin-1β, interleukin-6, tumor necrosis factor-α, sucrase, maltase, trypsin, myeloperoxidase, xanthine oxidase activities, protein carbonyl contents and sialic acid levels were raised in the damaged groups. Treatment with metformin restored all of this. The histological assessment revealed moderate to severe damage in the small intestine following processes D and C. According to the study's findings, metformin treatment led to a notable decline in histopathological damage in the C and DC. A slight lowering in inflammatory cells and an improvement in the damaged gland integrity in the small intestine were noted with metformin treatment.​ Metformin use protected the small intestinal tissue damage and decreased oxidative stress.
Competing Interests: Declarations Ethical approval All experimental protocols were approved by the Animal Care and Use Committee of the Istanbul University, Istanbul, Turkey (ethics committee decision number 2014/28) and carried out in compliance with the ARRIVE guidelines. All animal experiments were conducted following the national guidelines and the relevant national laws on the protection of animals. Competing interests The authors declare no competing interests.
(© 2024. The Author(s), under exclusive licence to Springer Nature B.V.)
Databáze: MEDLINE
Externí odkaz: